The agency granted approval of the medication to drugmaker Allergan USA, which brought in more than $4 billion in net revenue in the third quarter of this year, according to internal data. Its extensive portfolio of medications also include popular drugs like Botox.
Ubrelvy is an oral calcitonin gene-related peptide receptor antagonist now approved for the treatment of acute migraines, an FDA press announcement reported. The grant was awarded to Allergan USA, Inc. In clinical trials conducted on over 1,400, the medication was found to be effective in the quick treatment of migraine.